Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electroconvulsive therapy vs. esketamine nasal spray in treatment-resistant depression
2020-004172-17Phase 4Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by Medical University of Innsbruck. Started Mar 2021; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-004172-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004172-17.